696P Is it possible to improve the prognostic ability of the IMDC score? Validation of the Meet-URO score in metastatic renal cell carcinoma (mRCC) patients (pts) receiving first-line nivolumab plus ipilimumab in the Italian Expanded Access Program (EAP)

2021 ◽  
Vol 32 ◽  
pp. S709
Author(s):  
S.E. Rebuzzi ◽  
A. Signori ◽  
M. Maruzzo ◽  
G. Tortora ◽  
L. Galli ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
First Line ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

REACT expanded-access program in patients with metastatic renal cell carcinoma: real-world data from a European subanalysis

2015 ◽  
Vol 11 (21) ◽  
pp. 2893-2903 ◽  
Author(s):  
Sergio Bracarda ◽  
Sylvie Rottey ◽  
Amit Bahl ◽  
Christian Eichelberg ◽  
Begoña Mellado ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Real World ◽  
Renal Cell ◽  
Real World Data ◽  
World Data ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

scholarly journals Cabozantinib in metastatic renal cell carcinoma (mRCC): Data from UK expanded access program (EAP)

2018 ◽  
Vol 29 ◽  
pp. viii317
Author(s):  
A. Gomez de Liano Lista ◽  
B. Venugopal ◽  
K. Fife ◽  
S. Symeonides ◽  
N.S. Vasudev ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

scholarly journals OUTCOME OF METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED BY ANTI-PD-1 THERAPY IN EXPANDED ACCESS PROGRAM: CLINICAL EFFICACY AND POTENTIAL BIOMARKERS FOR NIVOLUMAB THERAPY

2018 ◽  
Vol 8 (3) ◽  
pp. 31-38
Author(s):  
M. S. Sayapina ◽  
N. A. Savyolov ◽  
N. V. Lyubimova ◽  
Yu. S. Timofeev ◽  
D. A. Nosov
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Progression Free Survival ◽  
Immune Checkpoints ◽  
Free Survival ◽  
Expanded Access ◽  
Expanded Access Program ◽  
Access Program

Therapy with immune checkpoints inhibitors (anti-PD-1 therapy) has become the standard of care for metastatic renal cell carcinoma (mRCC) patients with resistance to tyrosine kinase inhibitors (TKI). Identification of reliable predictive markers for anti-PD-1 therapy would help to select patients who are most likely to respond to checkpoints inhibitors. This article represents the results of treatment of 23 mRCC patients who received nivolumab as part of the expanded access program in Russia. All patients demonstrated resistance to previous lines of TKI therapy. Overall response rate for nivolumab was 21.7 % with median progression-free survival of 4 months (95%CI=1.37–10.04). The median overall survival was not reached with the median follow-up of 10 months (3–14 months). The grade 3–4 toxicity was observed in 3 (13 %) pts. Favorable MSKCC prognosis before treatment, the initial level of sPD-1 exceeding the estimated threshold value and the development of any grade hypothyroidism after treatment initiation were associated with greater progression free survival. The number of preceding lines of TKI therapy, the level of PD-L1 and FOXP3 expression on tumor-infiltrating leukocytes (TILs) did not significantly affect progression-free survival in this group of mRCC patients. The ef ficacy and toxicity profile of nivolumab corresponded to the results of phase 2–3 trials.

Sign in / Sign up

Export Citation Format

Share Document